All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through a grant from Bristol Myers Squibb and Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
How can a variant of CSF2RB drive leukemogenesis in Down's syndrome?
Bookmark this article
During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to Leila Varghese, Ludwig Institute for Cancer Research, Brussels, BE. We asked: How can a variant of CSF2RB drive leukemogenesis in Down's syndrome?
Thanks to next-generation sequencing, a number of variants have been associated with AML establishment and progression. However, the question remains: do these variants drive disease and, if so, how?
Patients with Down's syndrome are at much higher risk of developing AML, and a mutation in the cytokine receptor CSF2RB is of particular interest in these patients. Here, Leila Varghese discusses the findings from preclinical studies investigating the involvement of a CSF2RB variant in leukemic cell proliferation.
How can a variant of CSF2RB drive leukemogenesis in Down's syndrome?
More about...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox